Información del artículo
El Texto completo está disponible en PDF
References
[1.]
S. Brown, H. Inskip, B. Barraclough.
Causes of the excess mortality of schizophrenia.
Br J Psychiatry, 177 (2000), pp. 212-217
[2.]
B. Dickey, S.L.T. Normand, R.D. Weiss, R.E. Drake, H. Azeni.
Medical morbidity, mental illness and substance use disorders.
Psychiatric Services, 53 (2002), pp. 861-867
[3.]
D.M. Lawrence, C.D.J. Holman, A.V. Jablensky, M.S.T. Hobbs.
Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980–1998.
Br J Psychiatry, 182 (2003), pp. 31-36
[4.]
R. Filik, A. Sipos, P.G. Kehoe, T. Burns, S.J. Cooper, H. Stevens, et al.
The cardiovascular and respiratory health of people with schizophrenia.
Acta Psychiatr Scand, 113 (2006), pp. 298-305
[5.]
J. Cradock-O’Lealry, A.S. Young, E.M. Yano, M. Wang, M.L. Lee.
Use of general medical services by VA patients with psychiatric disorders.
Psychiatr Serv, 53 (2002), pp. 874-878
[6.]
G.L. Daumit, P.J. Pronovost, C.B. Anthony, E. Guallar, D.M. Steinwachs, D.E. Ford.
Adverse events during medical and surgical hospitalizations for persons with schizophrenia.
Arch Gen Psychiatry, 63 (2006), pp. 267-272
[7.]
J. De Leon, F.J. Diaz.
A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors.
Schizophr Res, 76 (2005), pp. 135-157
[8.]
R.C. Kessler, K.A. McGonagle, S. Zhao, C.B. Nelson, M. Hughes, S. Eshleman, et al.
Lifetime and 12-month prevalence of DSMIII-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.
Arch Gen Psychiatry, 51 (1994), pp. 8-19
[9.]
S. Brown, J. Birtwistle, L. Roe, C. Thompson.
The unhealthy lifestyle of people with schizophrenia.
Psychol Med, 29 (1999), pp. 697-701
[10.]
R.G. McCreadie.
Diet, smoking and cardiovascular risk in people with schizophrenia.
Br J Psychiatry, 183 (2003), pp. 534-539
[11.]
D.B. Allison, D.E. Casey.
Antipsychotic-induced weight gain: a review of the literature.
J Clin Psychiatry, 62 (2001), pp. 22-31
[12.]
M.J. Sernyak, D.L. Leslie, R.D. Alarcon, M.F. Losonczy, R. Rosenheck.
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Am J Psychiatry, 159 (2002), pp. 561-566
[13.]
C.E. Koro, D.O. Fedder, G.J. L’Italien, S. Weiss, L.S. Magder, J. Kreyenbuhl, et al.
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
Arch Gen Psychiatry, 59 (2002), pp. 1021-1026
[14.]
B.G. Druss, R.A. Rosenheck.
Mental disorders and access to medical care in the United States.
Am J Psychiatry, 155 (1998), pp. 1775-1777
[15.]
E.K. Koranyi.
Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinical population.
Arch Gen Psychiatry, 36 (1979), pp. 414-419
[16.]
D.V. Jeste, J.A. Gladsjo, L.A. Lindamer, J.P. Lacro.
Medical comorbidity in schizophrenia.
Schizophr Bull, 22 (1996), pp. 413-430
[17.]
L.S. Goldman.
Medical illness in patients with schizophrenia.
J Clin Psychiatry, 60 (1999), pp. 10-15
[18.]
D.F. Bunce II, L.R. Jones, L.W. Badger, S.E. Jones.
Medical illness in psychiatric patients: barriers to diagnosis and treatment.
South Med J, 75 (1982), pp. 941-944
[19.]
R.H. Dworkin.
Pain insensitivity in schizophrenia: a neglected phenomenon and some implications.
Schizophr Bull, 20 (1994), pp. 235-248
[20.]
D.M. Ziedonis, T.P. George.
Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues.
Schizophr Bull, 23 (1997), pp. 347-354
Copyright © 2009. SEP y SEPB